News

Vetoquinol Reports Strong Growth in Sales by September 2024

Vetoquinol Reports Strong Growth in Sales by September 2024

Vetoquinol's Sales Performance as of September 2024

At the conclusion of September 2024, Vetoquinol (Paris: VETO) reported impressive sales figures totaling €398 million. This reflects a growth of +1.6% when noted on a reported basis and an increase of +1.8% when accounting for constant exchange rates. Over this period, Vetoquinol faced net negative currency impacts amounting to €-1 million primarily linked to the Americas and Asia Pacific/Rest of World regions. However, these were partially offset by a positive currency impact of €1.4 million attributed to the European market.

Essential Products Contribution

Significantly, the sales from essential products hit €241 million. This represents a commendable growth of +3.9% as reported and similarly at constant exchange rates. By September 30, 2024, essential products made up 61% of the total sales for the laboratory, marking an increase from 59% during the same time in 2023.

Geographic Performance Overview

In terms of strategic territories, sales in Europe and Asia-Pacific/Rest of World demonstrated steady growth, with increases of +3.6% and +12.3%, respectively. However, the United States market faced a decline of -11.5%. This decrease is attributed to previously mentioned issues from the presentation of the Half-Year Results 2024, particularly a decrease in inventories among American wholesalers and the temporary unavailability of certain products. Excluding the United States, the Americas territory observed a robust increase of +7.6%.

Sales by Animal Category

Evaluating further into product categories, Vetoquinol reported sales of €281 million for companion animal products, which saw a growth of 1.6% at constant exchange rates. These sales accounted for 70.4% of the total sales, demonstrating the company’s significant focus on this segment. On the other hand, sales for farm animals were reported at €117 million, which increased by +2.0% when examined at constant exchange rates.

Quarterly Insights

In the third quarter of FY 2024, Vetoquinol's sales reached €134 million, which remained stable with a slight decrease of -0.5% at constant exchange rates. The foreign exchange scenario had a negative impact of €1 million (-1.0%), significantly affecting the Americas region excluding the United States. Notably, the laboratory's cash position exhibited improvement throughout the third quarter.

Future Expectations

While the sales for the first nine months of 2024 remain unaudited by the Statutory Auditors, stakeholders are eagerly anticipating future publications. The next significant announcement regarding annual sales is expected on January 30, 2025, after market close.

About Vetoquinol

Founded in 1933, Vetoquinol has emerged as a notable independent player in the animal health sector, operating extensively across Europe, the Americas, and Asia/Pacific. The company focuses on the innovation, development, and marketing of veterinary medicines, as well as non-medicated products for both farm animals, such as cattle and pigs, and pets, including dogs and cats. Vetoquinol’s commitment to expanding its product portfolio and pursuing strategic acquisitions in high-potential regions has contributed to its hybrid growth model. As of June 30, 2024, the company employed a workforce of 2,519 individuals.

Conclusion and Forward-Looking Indicators

Vetoquinol continues to guide its growth trajectory through strong product offerings and regional expansions. The company's focus on essential products is evidently paying off. As Vetoquinol seeks to maintain this growth momentum, it is poised to harness its broad market reach and innovative capabilities to remain competitive in animal health.

Frequently Asked Questions

What were Vetoquinol's total sales by September 2024?

Vetoquinol's sales totaled €398 million by the end of September 2024.

How did essential products perform in sales?

Sales of essential products reached €241 million, growing by +3.9% on a reported basis.

What challenges did Vetoquinol face in the U.S. market?

The U.S. market encountered a decline of -11.5% due to inventory reductions and product availability issues.

What percentage of Vetoquinol's sales are from companion animals?

Sales from companion animals accounted for 70.4% of Vetoquinol’s total sales in this reporting period.

What is Vetoquinol's focus for future growth?

Vetoquinol aims to enhance its essential products and expand its market presence through strategic acquisitions and innovations.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 0

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 177

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Gayatri Pariwar Celebrates 100 Years with Massive Yoga Event

Updated Category News Views 52

An Impressive Centenary for Gayatri Pariwar Sometimes, you get hit by a wave so big you can't ignore it, and Gayatri Pariwar's centennial festival in New Delhi was one such tsunami. Picture this: countless souls gathered to mark a hundred years of spiritual and social reform, not just with chants and talks, but through an awe-inspiring mass yoga event. In my decades...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 231

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 459

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 23

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 54

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading
Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 46

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 373

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 142

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading

Top 5 Most Recently Viewed Articles

Bitcoin’s Price Dynamics: Labor Reports and Elections Impacting Trends

Updated Category News Views 197

Labor Market Reports and Bitcoin's Future Into The Cryptoverse founder Benjamin Cowen shares insights on the current trajectory of Bitcoin as market dynamics shift with upcoming labor market reports and election results. Market Predictions Impacted by External Factors Cowen emphasizes that predictions in the short term remain complex. He notes that the momentum of the...

Continue Reading
Wearable Materials Market Forecast: Growth to USD 9.14 Billion

Updated Category News Views 238

Overview of the Wearable Materials Market The Wearable Materials Market is on an impressive trajectory, with an anticipated growth from USD 3.24 billion in 2024 to USD 9.14 billion by 2032. This surge represents a compounded annual growth rate (CAGR) of 13.85% during the forecast years. Such expansion is astonished by the increasing demand for wearables associated with...

Continue Reading
Strengthening Ties: Xi Jinping and Singaporean PM Wong Unite

Updated Category News Views 382

Strengthening Bilateral Relations for a Brighter Future In a significant meeting that highlights the growing ties between China and Singapore, President Xi Jinping recently welcomed Singaporean Prime Minister Lawrence Wong in Beijing. This engagement underscores the deepening friendship and collaboration between the two nations. During their discussions, President Xi...

Continue Reading
Exploring the Rapid Growth of the Virtual Cards Market

Updated Category News Views 154

Overview of the Virtual Cards Market The global virtual cards market is poised for substantial growth, with estimates suggesting an increase of USD 428.6 billion from 2025 to 2029. A significant annual growth rate of 17.1% during this period is projected, reflecting the ongoing transformations in the payment landscape, particularly driven by advancements in technology and...

Continue Reading
Appian Introduces Advanced AI Features to Revolutionize Workflow

Updated Category News Views 240

Transforming Business Processes with AI Appian, renowned for its innovative process automation solutions, has just rolled out significant enhancements to its platform. By embedding sophisticated AI agents into enterprise workflows, Appian is making strides in automating complex tasks, and empowering business users to revamp outdated applications seamlessly. Empowering...

Continue Reading